Adalimumab biosimilar (Pfizer)

阿达木单抗生物类似药（辉瑞）

Report date: 2024/01/15 10:55:57

Base Information

Drug NameAdalimumab biosimilar (Pfizer)
Drug Alias Name阿达木单抗生物仿制药（辉瑞）Adalimumab biosimilar (pfizer)Adalimumab-afzbAmsparityAbrilada +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitisCrohn Disease +[9] 
Global Approved IndicationsPsoriasisUveitisCrohn Disease +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/15
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Europe Ma Eeig
Inactive CompaniesN/A
Active IndicationsPsoriasisUveitisCrohn Disease +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksWikipediaDrugBankKEGG